Channa Jayasena is Clinical Senior Lecturer and Consultant in Reproductive Endocrinology and Andrology at Imperial College and Hammersmith Hospital, London. Dr. Jayasena qualified in medicine at Cambridge University, after which he undertook specialist training in Diabetes & Endocrinology in London. Having been awarded a Wellcome Trust Clinical Research Training Fellowship and NIHR Clinical Lectureship, he conducted first-to-human studies at Imperial College investigating the clinical effects of novel hypothalamic neuropeptides such as kisspeptin on the human reproductive axis. He is currently Clinical Lead for Male Infertility / Andrology at Hammersmith Hospital which has developed cutting edge techniques such as seminal reactive oxygen species (ROS) measurement, microsurgical testicular sperm extraction (mTESE) and testicular mapping. His current research focuses on developing novel diagnostics and therapeutics for men with disorders of spermatogenesis.
Wernig F, Jayasena CN, Dhillo WS, 2017, Carcinoid syndrome and neuroendocrine tumours, Medicine (united Kingdom), Vol:45, ISSN:1357-3039, Pages:543-546
et al., 2017, Presentation, Treatment, and Prognosis of secondary Melanoma within the Orbit, Frontiers in Oncology, Vol:7, ISSN:2234-943X
et al., 2017, Neurokinin 3 receptor antagonism as a novel treatment for menopausal hot flushes: a phase 2, randomised, double-blind, placebo-controlled trial, Lancet, Vol:389, ISSN:0140-6736, Pages:1809-1820
et al., 2017, Mechanistic insights into the more potent effect of KP-54 compared to KP-10 in vivo, Plos One, Vol:12, ISSN:1932-6203
et al., 2017, Kisspeptin modulates sexual and emotional brain processing in humans, Journal of Clinical Investigation, Vol:127, ISSN:0021-9738, Pages:709-719